NCT07387302Not yet recruitingPhase 2
SLN12140 in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
A Phase II Clinical Study Evaluating SLN12140 in Complement Inhibitor-Naïve Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if drug SLN12140 works to treat Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria in adults. It will also learn about the safety, pharmacokinetic characteristics, and dosing of drug SLN12140. The study is divided into four phases: screening period, core treatment period, extended dosing period, and follow-up period, and includes two cohorts (Cohorts 1-2), with each cohort enrolling at least 5 treatment-naïve adult PNH subjects for complement inhibitor therapy.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 22 Jan 2026
- Start date
- Feb 2026
- Primary completion date
- Jul 2026
- Lead sponsor
- Linno Pharmaceuticals, Inc.
- NCT number
- NCT07387302
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 10
- From Feb 2026 to the primary completion date, Jul 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Significant bone marrow failure
- Meningitidis infection or unresolved meningococcal disease
- Other significant systemic diseases that might have impact on efficacy and safety assessment
Who the study is looking for
- Adult complement inhibitor naïve PNH patients (age\>=18), which is confirmed by flow cytometry evaluation
- Must be vaccinated against meningococcal vaccine and pneumococcal vaccine
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.